Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
RPTX Stock Forecast 2026-2027
$2.65
Current Price
$114.24M
Market Cap
Buy 1
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to RPTX Price Targets
+13.2%
To High Target of $3.00
+13.2%
To Median Target of $3.00
+13.2%
To Low Target of $3.00
RPTX Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+80.3%
1 Year Change
+1.9%
Year-to-Date Change
-0.4%
From 52W High of $2.66
+197.8%
From 52W Low of $0.89
๐ TOP ANALYST CALLS
Did RPTX Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if Repare Therapeutics is one of their latest high-conviction picks.
Latest RPTX Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, RPTX has a neutral consensus with a median price target of $3.00 (ranging from $3.00 to $3.00). The overall analyst rating is N/A (N/A/10). Currently trading at $2.65, the median forecast implies a 13.2% upside. This outlook is supported by 1 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Robert Burns at HC Wainwright & Co., projecting a 13.2% upside. Conversely, the most conservative target is provided by Robert Burns at HC Wainwright & Co., suggesting a 13.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RPTX Analyst Ratings
1
Buy
1
Hold
0
Sell
RPTX Price Target Range
Low
$3.00
Average
$3.00
High
$3.00
Current: $2.65
Latest RPTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RPTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 27, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $3.00 |
| Mar 7, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $5.00 |
| Dec 13, 2024 | LifeSci Capital | Charles Zhu | Market Perform | Downgrade | $N/A |
| Dec 13, 2024 | Stifel | Benjamin Burnett | Buy | Maintains | $4.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| Oct 24, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| Sep 23, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| Sep 4, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| Jun 5, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| May 30, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| Mar 8, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| Feb 21, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| Feb 14, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $10.00 |
| Nov 20, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $25.00 |
| Oct 16, 2023 | Piper Sandler | Joseph Catanzaro | Overweight | Maintains | $25.00 |
| Sep 25, 2023 | Stifel | Benjamin Burnett | Buy | Maintains | $17.00 |
| Aug 17, 2023 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jun 9, 2023 | Stifel | Benjamin Burnett | Buy | Upgrade | $16.00 |
| Jun 9, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $26.00 |
| Apr 27, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $25.00 |
Repare Therapeutics Inc. (RPTX) Competitors
The following stocks are similar to Repare Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
RPTX
Repare Therapeutics
mkt cap
114.24M
Repare Therapeutics Inc. (RPTX) Financial Data
Repare Therapeutics Inc. has a market capitalization of $114.24M with a P/E ratio of -1.3x. The company generates $11.87M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +4,548.0% quarter-over-quarter, while maintaining an operating margin of -3.7% and return on equity of -49.8%.
Valuation Metrics
Market Cap
$114.24M
Enterprise Value
$1.65M
P/E Ratio
-1.3x
PEG Ratio
0.0x
Price/Sales
9.6x
Growth & Margins
Revenue Growth (YoY)
+4,548.0%
Gross Margin
N/A
Operating Margin
-3.7%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+98.9%
Current Ratio
10.7x
Debt/Equity
0.3x
ROE
-49.8%
ROA
-29.7%
๐ก SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Repare Therapeutics Inc. (RPTX) Business Model
About Repare Therapeutics Inc.
What They Do
Develops innovative cancer therapies using precision medicine.
Business Model
Repare Therapeutics focuses on creating therapeutics that exploit genetic vulnerabilities in cancer cells through a strategy known as synthetic lethality. By identifying specific genes that can be targeted to kill cancer cells while preserving healthy ones, the company aims to advance novel cancer treatments and generate revenue through biopharmaceutical product development.
Additional Information
The company invests significantly in research and development to discover new therapies, positioning itself within the biopharmaceutical sector. Its collaborations with global scientific experts enhance its capabilities in cancer genetics research, potentially leading to breakthroughs in personalized medicine.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
129
CEO
Mr. Steve Forte CPA
Country
Canada
IPO Year
2020
Website
www.reparerx.comRepare Therapeutics Inc. (RPTX) Latest News & Analysis
Latest News
Quick Summary
Repare Therapeutics Inc. (Nasdaq: RPTX) announced that shareholders approved its acquisition by XenoTherapeutics, Inc. and Xeno Acquisition Corp.
Why It Matters
Repare Therapeutics' acquisition by XenoTherapeutics may signal a strategic shift in oncology research, potentially affecting stock valuations and investor confidence in both companies.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Repare Therapeutics has entered into an asset purchase agreement with Gilead Sciences for its Polฮธ ATPase inhibitor, RP-3467, aiming to enhance oncology research and development.
Why It Matters
Gilead's acquisition of Repare's RP-3467 enhances its oncology portfolio, potentially boosting future revenue and market position, impacting investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Repare Therapeutics (Nasdaq: RPTX) announced a definitive agreement for acquisition by XenoTherapeutics and Xeno Acquisition Corp., expected to affect all common shares.
Why It Matters
The acquisition by Xeno highlights Repare's strategic positioning in the oncology sector, potentially unlocking value and influencing stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value
6 months ago
Quick Summary
XenoTherapeutics Inc. and Xeno Acquisition Corp. have agreed to acquire Repare Therapeutics Inc. (NASDAQ: RPTX), potentially impacting the biotech sector.
Why It Matters
The acquisition of Repare Therapeutics by XenoTherapeutics could impact stock prices, investor sentiment, and market dynamics in the biotech sector, influencing investment strategies.
Source: Benzinga
Market Sentiment:
Positive
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Repare Therapeutics Inc. (NASDAQ: RPTX)
6 months ago
Quick Summary
Monteverde & Associates is investigating Repare Therapeutics' sale to XenoTherapeutics. Shareholders may receive $1.82 per share plus contingent value rights upon closing.
Why It Matters
The investigation into Repare Therapeutics' sale may signal concerns over the fairness of the cash offer and contingent value rights, potentially affecting shareholder sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Halper Sadeh LLC Encourages RPTX and SEE Shareholders to Contact the Firm to Discuss Their Rights
6 months ago
Quick Summary
Shareholders are urged to contact the firm promptly due to potential time constraints on enforcing their rights.
Why It Matters
Limited time to enforce shareholder rights suggests potential legal issues or corporate governance changes, impacting stock value and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About RPTX Stock
What is Repare Therapeutics Inc.'s (RPTX) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Repare Therapeutics Inc. (RPTX) has a median price target of $3.00. The highest price target is $3.00 and the lowest is $3.00.
Is RPTX stock a good investment in 2026?
According to current analyst ratings, RPTX has 1 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.65. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RPTX stock?
Wall Street analysts predict RPTX stock could reach $3.00 in the next 12 months. This represents a 13.2% increase from the current price of $2.65. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Repare Therapeutics Inc.'s business model?
Repare Therapeutics focuses on creating therapeutics that exploit genetic vulnerabilities in cancer cells through a strategy known as synthetic lethality. By identifying specific genes that can be targeted to kill cancer cells while preserving healthy ones, the company aims to advance novel cancer treatments and generate revenue through biopharmaceutical product development.
What is the highest forecasted price for RPTX Repare Therapeutics Inc.?
The highest price target for RPTX is $3.00 from Robert Burns at HC Wainwright & Co., which represents a 13.2% increase from the current price of $2.65.
What is the lowest forecasted price for RPTX Repare Therapeutics Inc.?
The lowest price target for RPTX is $3.00 from Robert Burns at HC Wainwright & Co., which represents a 13.2% increase from the current price of $2.65.
What is the overall RPTX consensus from analysts for Repare Therapeutics Inc.?
The overall analyst consensus for RPTX is neutral. Out of 6 Wall Street analysts, 1 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are RPTX stock price projections?
Stock price projections, including those for Repare Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 4, 2026 2:06 PM UTC